Cover Image
市場調查報告書

咳嗽:開發中產品分析

Cough - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192540
出版日期 內容資訊 英文 96 Pages
訂單完成後即時交付
價格
Back to Top
咳嗽:開發中產品分析 Cough - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 96 Pages
簡介

咳嗽是喉嚨為了排除黏膜或侵入的刺激物所發生的反射動作。因素為氣喘、慢性阻塞性肺病(COPD)、抽煙、支氣管擴張症等肺部疾病、間質性肺病變或腫瘤、肺炎和急性支氣管炎等肺部感染疾病及過敏性鼻子鼻竇炎等。治療方法有使用止咳藥藥、口服祛痰藥,及局部用藥物等。

本報告涵蓋全球咳嗽治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

簡介

  • 調查範圍

咳嗽概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

咳嗽:企業開發中的治療藥

咳嗽:大學/研究機關研究中的治療藥

咳嗽:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

咳嗽:企業開發中的產品

咳嗽:大學/研究機關研究中的產品

咳嗽的治療藥開發企業

  • Afferent Pharmaceuticals, Inc.
  • Alitair Pharmaceuticals, Inc.
  • Alveonix AG
  • AstraZeneca Plc
  • AusBio Ltd
  • Charleston Laboratories, Inc.
  • Conrig Pharma ApS
  • Daewoong Pharmaceutical Co., Ltd.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • GW Pharmaceuticals Plc
  • Hyundai Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • NeRRe Therapeutics Ltd
  • Orbis Biosciences Inc
  • Patara Pharma, Inc.
  • Pila Pharma AB
  • Vernalis Plc

咳嗽:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

咳嗽:暫停中的計劃

咳嗽:開發中止的產品

咳嗽:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8422IDB

Summary

Global Markets Direct's, 'Cough - Pipeline Review, H2 2016', provides an overview of the Cough pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cough
  • The report reviews pipeline therapeutics for Cough by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cough therapeutics and enlists all their major and minor projects
  • The report assesses Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cough

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cough
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cough Overview
  • Therapeutics Development
    • Pipeline Products for Cough - Overview
    • Pipeline Products for Cough - Comparative Analysis
  • Cough - Therapeutics under Development by Companies
  • Cough - Therapeutics under Investigation by Universities/Institutes
  • Cough - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Cough - Products under Development by Companies
  • Cough - Products under Investigation by Universities/Institutes
  • Cough - Companies Involved in Therapeutics Development
    • Afferent Pharmaceuticals, Inc.
    • Alitair Pharmaceuticals, Inc.
    • Alveonix AG
    • AstraZeneca Plc
    • AusBio Ltd
    • Charleston Laboratories, Inc.
    • Conrig Pharma ApS
    • Daewoong Pharmaceutical Co., Ltd.
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd.
    • GW Pharmaceuticals Plc
    • Hyundai Pharmaceutical Co., Ltd.
    • Johnson & Johnson
    • NeRRe Therapeutics Ltd
    • Orbis Biosciences Inc
    • Patara Pharma, Inc.
    • Pila Pharma AB
    • Vernalis Plc
  • Cough - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Ax-8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benzonatate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-07 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLAT-313 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • codeine + guaifenesin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cromolyn sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWJ-1340 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRC-17536 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2339345 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • guaifenesin + hydrocodone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • guaifenesin ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-39729209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lesogaberan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levodropropizine CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MD-990 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-7264 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEO-5937 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • orvepitant maleate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-1226 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XEND-0501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cough - Dormant Projects
  • Cough - Discontinued Products
  • Cough - Product Development Milestones
    • Featured News & Press Releases
      • Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study
      • May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference
      • May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors
      • Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference
      • Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study
      • Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study
      • Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study
      • Oct 12, 2015: Vernalis announces start of CCP-08 12 month stability testing
      • Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial
      • Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
      • Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing
      • Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet
      • Sep 09, 2014: Charleston Laboratories Announces Key Clinical Updates for Novel Drug
      • Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept
      • Apr 29, 2014: Second Product in Vernalis' Cough Cold Pipeline Achieves Proof-of-Concept
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cough, H2 2016
  • Number of Products under Development for Cough - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Cough - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016
  • Cough - Pipeline by Alitair Pharmaceuticals, Inc., H2 2016
  • Cough - Pipeline by Alveonix AG, H2 2016
  • Cough - Pipeline by AstraZeneca Plc, H2 2016
  • Cough - Pipeline by AusBio Ltd, H2 2016
  • Cough - Pipeline by Charleston Laboratories, Inc., H2 2016
  • Cough - Pipeline by Conrig Pharma ApS, H2 2016
  • Cough - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Cough - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
  • Cough - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Cough - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Cough - Pipeline by Johnson & Johnson, H2 2016
  • Cough - Pipeline by NeRRe Therapeutics Ltd, H2 2016
  • Cough - Pipeline by Orbis Biosciences Inc, H2 2016
  • Cough - Pipeline by Patara Pharma, Inc., H2 2016
  • Cough - Pipeline by Pila Pharma AB, H2 2016
  • Cough - Pipeline by Vernalis Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cough - Dormant Projects, H2 2016
  • Cough - Dormant Projects (Contd..1), H2 2016
  • Cough - Dormant Projects (Contd..2), H2 2016
  • Cough - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Cough, H2 2016
  • Number of Products under Development for Cough - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top